(Q43752867)

26 November 2017

title

Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model (English)

1 reference

26 November 2017

Berman JD

1

1 reference

26 November 2017

Nielsen R

2

1 reference

26 November 2017

Chulay JD

3

1 reference

26 November 2017

Dowler M

4

1 reference

26 November 2017

Kain KC

5

1 reference

26 November 2017

Kester KE

6

1 reference

26 November 2017

Williams J

7

1 reference

26 November 2017

Whelen AC

8

1 reference

26 November 2017

Shmuklarsky MJ

9

1 reference

26 November 2017

publication date

1 July 2001

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

26 November 2017

published in

1 reference

26 November 2017

volume

95

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

429-432

1 reference

In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Challenges in the development of antimalarial drugs with causal prophylactic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

High-performance liquid chromatographic assay for the measurement of atovaquone in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Activity of dihydrofolate reductase inhibitors on the hepatic stages of Plasmodium yoelii yoelii in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Researches on paludrine (M.4888) in malaria; an experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F.) Cairns, Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Malaria chemoprophylaxis with tafenoquine: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Atovaquone and proguanil for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

The pre-erythrocytic stage of Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

Prophylactic activity of atovaquone against Plasmodium falciparum in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2801%2990206-8

7 January 2021

10.1016/S0035-9203(01)90206-8

Identifiers

DOI

1 reference

26 November 2017

1 reference